 Seena Aisner
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 1 | 2022 | 49 | 0.720 |
Why?
| | Soft Tissue Neoplasms | 5 | 2009 | 113 | 0.600 |
Why?
| | Bone Neoplasms | 4 | 2008 | 242 | 0.480 |
Why?
| | Thymus Neoplasms | 3 | 2011 | 23 | 0.480 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 1068 | 0.460 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 1474 | 0.450 |
Why?
| | Lung Neoplasms | 10 | 2017 | 2508 | 0.400 |
Why?
| | Octreotide | 2 | 2010 | 25 | 0.380 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2010 | 6 | 0.380 |
Why?
| | Liposarcoma | 3 | 2009 | 27 | 0.370 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2264 | 0.360 |
Why?
| | Prednisone | 2 | 2010 | 215 | 0.360 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2010 | 162 | 0.350 |
Why?
| | Lipoma | 2 | 2009 | 17 | 0.350 |
Why?
| | Translocation, Genetic | 3 | 2010 | 104 | 0.340 |
Why?
| | Receptor, ErbB-2 | 3 | 2010 | 339 | 0.330 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2010 | 49 | 0.320 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 68 | 0.320 |
Why?
| | Chondroblastoma | 2 | 2006 | 3 | 0.310 |
Why?
| | Biopsy, Fine-Needle | 4 | 2014 | 67 | 0.300 |
Why?
| | ErbB Receptors | 3 | 2016 | 603 | 0.290 |
Why?
| | Fibula | 1 | 2008 | 41 | 0.280 |
Why?
| | Nevus, Spindle Cell | 1 | 2007 | 1 | 0.280 |
Why?
| | Angiofibroma | 1 | 2007 | 6 | 0.280 |
Why?
| | Biomarkers, Tumor | 5 | 2017 | 1250 | 0.270 |
Why?
| | Leiomyoma | 1 | 2008 | 78 | 0.260 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2006 | 11 | 0.260 |
Why?
| | Tibia | 1 | 2008 | 178 | 0.250 |
Why?
| | Femoral Neoplasms | 1 | 2006 | 9 | 0.250 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 553 | 0.240 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 199 | 0.240 |
Why?
| | Image Enhancement | 1 | 2006 | 167 | 0.240 |
Why?
| | Cheek | 1 | 2004 | 17 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2017 | 1062 | 0.230 |
Why?
| | Facial Neoplasms | 1 | 2004 | 19 | 0.230 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2016 | 98 | 0.220 |
Why?
| | Immunohistochemistry | 10 | 2014 | 1726 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 1697 | 0.200 |
Why?
| | Microtomy | 1 | 2003 | 5 | 0.200 |
Why?
| | Pain | 2 | 2008 | 751 | 0.200 |
Why?
| | Cytological Techniques | 1 | 2003 | 26 | 0.200 |
Why?
| | Biopsy, Needle | 1 | 2003 | 188 | 0.190 |
Why?
| | Vulvar Neoplasms | 1 | 2022 | 13 | 0.190 |
Why?
| | Subcutaneous Tissue | 1 | 2022 | 24 | 0.190 |
Why?
| | Paclitaxel | 2 | 2014 | 239 | 0.180 |
Why?
| | Middle Aged | 25 | 2019 | 33242 | 0.180 |
Why?
| | Hypothalamus | 1 | 2022 | 152 | 0.180 |
Why?
| | Breast | 1 | 2022 | 154 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3541 | 0.170 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2010 | 59 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2010 | 311 | 0.160 |
Why?
| | Vulva | 2 | 2022 | 24 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2006 | 849 | 0.150 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 152 | 0.150 |
Why?
| | Humans | 38 | 2022 | 136960 | 0.140 |
Why?
| | Thymoma | 2 | 2011 | 34 | 0.140 |
Why?
| | Aged | 19 | 2019 | 23838 | 0.140 |
Why?
| | Selenium | 2 | 2017 | 43 | 0.140 |
Why?
| | Female | 27 | 2022 | 73054 | 0.130 |
Why?
| | Male | 26 | 2017 | 67419 | 0.130 |
Why?
| | Urinary Bladder | 1 | 2019 | 183 | 0.130 |
Why?
| | Bevacizumab | 1 | 2017 | 135 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 71 | 0.130 |
Why?
| | Disease-Free Survival | 4 | 2013 | 671 | 0.130 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 41 | 0.130 |
Why?
| | Anilides | 1 | 2016 | 71 | 0.130 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 253 | 0.120 |
Why?
| | Adult | 18 | 2017 | 37690 | 0.120 |
Why?
| | Carcinoma | 2 | 2011 | 228 | 0.120 |
Why?
| | Neoplasm Staging | 4 | 2017 | 1369 | 0.120 |
Why?
| | Sputum | 1 | 2017 | 304 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 189 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2013 | 1388 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 233 | 0.110 |
Why?
| | Isotretinoin | 1 | 2014 | 26 | 0.110 |
Why?
| | DNA Methylation | 2 | 2017 | 642 | 0.110 |
Why?
| | Angiomatosis | 1 | 2013 | 5 | 0.110 |
Why?
| | Breast Diseases | 1 | 2013 | 22 | 0.110 |
Why?
| | Polyps | 1 | 2013 | 11 | 0.100 |
Why?
| | Vulvar Diseases | 1 | 2013 | 9 | 0.100 |
Why?
| | Adenoma, Oxyphilic | 1 | 2013 | 7 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 2 | 0.100 |
Why?
| | Genes, ras | 1 | 2013 | 96 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 8 | 0.100 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2013 | 39 | 0.100 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.100 |
Why?
| | Interferon-alpha | 1 | 2014 | 199 | 0.100 |
Why?
| | Pyridines | 1 | 2016 | 498 | 0.100 |
Why?
| | Immunoenzyme Techniques | 3 | 2016 | 208 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2010 | 24 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 66 | 0.090 |
Why?
| | Smad Proteins | 1 | 2012 | 42 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 65 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 369 | 0.090 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 19 | 0.090 |
Why?
| | Pneumonectomy | 3 | 2017 | 148 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 645 | 0.090 |
Why?
| | Carboplatin | 1 | 2011 | 142 | 0.090 |
Why?
| | Autophagy | 1 | 2013 | 286 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 903 | 0.080 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 75 | 0.080 |
Why?
| | World Health Organization | 1 | 2010 | 124 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2013 | 524 | 0.080 |
Why?
| | Tidal Volume | 1 | 2010 | 86 | 0.080 |
Why?
| | Positive-Pressure Respiration | 1 | 2010 | 81 | 0.080 |
Why?
| | Survival Analysis | 4 | 2017 | 1293 | 0.080 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2010 | 53 | 0.080 |
Why?
| | Fibroma | 1 | 2009 | 21 | 0.080 |
Why?
| | Genes, p16 | 1 | 2009 | 19 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 563 | 0.080 |
Why?
| | Cell Dedifferentiation | 1 | 2009 | 31 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 483 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2008 | 2677 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2016 | 3247 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2013 | 7596 | 0.070 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 211 | 0.070 |
Why?
| | Tissue Fixation | 2 | 2008 | 37 | 0.070 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2006 | 15 | 0.070 |
Why?
| | Collagen | 1 | 2009 | 449 | 0.060 |
Why?
| | Cytodiagnosis | 1 | 2006 | 33 | 0.060 |
Why?
| | Forkhead Box Protein O1 | 1 | 2006 | 32 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2008 | 204 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 525 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 159 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 391 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2142 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2006 | 149 | 0.060 |
Why?
| | Adenoma | 1 | 2008 | 230 | 0.060 |
Why?
| | Pain Measurement | 1 | 2008 | 523 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1024 | 0.060 |
Why?
| | Rare Diseases | 1 | 2006 | 105 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 457 | 0.060 |
Why?
| | Coccidioides | 1 | 2004 | 6 | 0.060 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 8 | 0.060 |
Why?
| | Shoulder Pain | 1 | 2004 | 34 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2378 | 0.060 |
Why?
| | Salivary Gland Neoplasms | 1 | 2004 | 36 | 0.060 |
Why?
| | Taxoids | 1 | 2004 | 101 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2007 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 651 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1414 | 0.050 |
Why?
| | Mesothelioma | 1 | 2004 | 44 | 0.050 |
Why?
| | Prognosis | 4 | 2016 | 3979 | 0.050 |
Why?
| | Osteosarcoma | 1 | 2004 | 73 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 190 | 0.050 |
Why?
| | Tissue Array Analysis | 2 | 2013 | 56 | 0.050 |
Why?
| | Sarcoma, Synovial | 1 | 2002 | 21 | 0.050 |
Why?
| | Fibroma, Desmoplastic | 1 | 2002 | 2 | 0.050 |
Why?
| | Artifacts | 1 | 2003 | 115 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 996 | 0.050 |
Why?
| | Ribs | 1 | 2002 | 34 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2017 | 10715 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 2015 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 749 | 0.040 |
Why?
| | Leukopenia | 2 | 2014 | 30 | 0.040 |
Why?
| | Fowlpox virus | 1 | 2019 | 1 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2126 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 16 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 1011 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5072 | 0.040 |
Why?
| | Paraffin Embedding | 2 | 2010 | 34 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2801 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1747 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1531 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 972 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2006 | 1292 | 0.030 |
Why?
| | International Agencies | 1 | 2016 | 36 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1751 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 420 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 388 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 73 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1346 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1911 | 0.030 |
Why?
| | Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 1 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 17 | 0.030 |
Why?
| | Adolescent | 4 | 2006 | 21463 | 0.030 |
Why?
| | Myxoma | 1 | 2013 | 12 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2013 | 79 | 0.030 |
Why?
| | Alopecia | 1 | 2013 | 32 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 172 | 0.030 |
Why?
| | Patient Selection | 1 | 2017 | 688 | 0.030 |
Why?
| | Genes, p53 | 1 | 2013 | 71 | 0.030 |
Why?
| | Cohort Studies | 2 | 2014 | 5679 | 0.030 |
Why?
| | Chemoprevention | 1 | 2013 | 92 | 0.030 |
Why?
| | Demography | 1 | 2013 | 290 | 0.020 |
Why?
| | Tamoxifen | 1 | 2013 | 202 | 0.020 |
Why?
| | Postoperative Period | 1 | 2013 | 341 | 0.020 |
Why?
| | Constipation | 1 | 2013 | 95 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 144 | 0.020 |
Why?
| | Microscopy | 1 | 2013 | 153 | 0.020 |
Why?
| | Longevity | 1 | 2013 | 174 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 391 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 948 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1455 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 555 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 336 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 872 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 656 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 98 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2843 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2010 | 122 | 0.020 |
Why?
| | Estradiol | 1 | 2013 | 521 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 64 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2016 | 944 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 157 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2009 | 55 | 0.020 |
Why?
| | Karyotyping | 1 | 2009 | 103 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 618 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 394 | 0.020 |
Why?
| | Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.020 |
Why?
| | Child | 2 | 2006 | 21775 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1728 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2009 | 56 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1905 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 968 | 0.020 |
Why?
| | Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Animals | 3 | 2019 | 36934 | 0.020 |
Why?
| | Fixatives | 1 | 2007 | 13 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 558 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2010 | 265 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 65 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2007 | 187 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 111 | 0.020 |
Why?
| | Swine | 1 | 2010 | 776 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 642 | 0.020 |
Why?
| | Anesthesia | 1 | 2010 | 189 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 13202 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 957 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 313 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 181 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2803 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2007 | 241 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2465 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 430 | 0.010 |
Why?
| | Preoperative Care | 1 | 2008 | 358 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 797 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3410 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 852 | 0.010 |
Why?
| | Itraconazole | 1 | 2004 | 6 | 0.010 |
Why?
| | Metacarpus | 1 | 2004 | 6 | 0.010 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2004 | 6 | 0.010 |
Why?
| | Hemodynamics | 1 | 2010 | 1066 | 0.010 |
Why?
| | Phenotype | 1 | 2013 | 3148 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 946 | 0.010 |
Why?
| | Agranulocytosis | 1 | 2004 | 31 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1237 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2014 | 15619 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 131 | 0.010 |
Why?
| | Pneumonia | 1 | 2010 | 632 | 0.010 |
Why?
| | Edema | 1 | 2004 | 129 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 158 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2004 | 232 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 390 | 0.010 |
Why?
| | Skin | 1 | 2007 | 747 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4095 | 0.010 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2002 | 45 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2002 | 110 | 0.010 |
Why?
| | Radiography | 1 | 2004 | 816 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2797 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2072 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1086 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 318 | 0.010 |
Why?
| | Survival Rate | 1 | 2004 | 1927 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 805 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5058 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1734 | 0.010 |
Why?
| | Lung | 1 | 2010 | 4031 | 0.010 |
Why?
| | Mice | 1 | 2013 | 17757 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1475 | 0.010 |
Why?
| | United States | 1 | 2004 | 14894 | 0.000 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|